Novartis stopped testing its ALS drug but bought a brain delivery system from Sironax for $1.

NVS · Novartis AG

The AI's read

The Phase 2 failure reduces the chances VHB937 will become an ALS treatment and removes an expected clinical read. Buying Sironax’s brain delivery platform gives Novartis a tool to move large biologics into the brain and broaden its neurological programs. Both facts are significant and pull in opposite directions, so I read the story as leaving Novartis’s outlook unchanged today.